NCT00654602View on ClinicalTrials.gov

48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

PHASE3CompletedINTERVENTIONAL

Enrollment

1,500

Participants

Timeline

Start Date

February 28, 2002

Study Completion Date

November 30, 2004

Conditions

Dyslipidaemia

Interventions

DRUG

Rosuvastatin

BEHAVIORAL

Maintenance of specific diet

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY